title: Overall condition improvement in a rat model of nephrotic syndrome treated with CellCept nanoliposomes.
abstract: Purpose To investigate the effect of CellCept nanoliposomes on Adriamycin-induced nephrotic syndrome in rats. Methods To model nephrotic syndrome, rats were injected with 6.5 mg/kg of Adriamycin in the tail vein. The rats were randomly divided into three groups, including a control group, a free mycophenolate mofetil (MMF)-treated group, and a liposome-encapsulated MMF-treated group. Five weeks after the Adriamycin treatment, the free MMF-treated group received CellCept while the liposome-encapsulated MMF-treated group received the CellCept nanoliposomes for 2 weeks. The general condition of the animals was observed, which included urine volume over 24 h, urine protein levels, and serum biochemical indexes. Renal morphology was also observed. Results The level of urine protein over 24 h was increased in the control group, while plasma albumin (ALB) was decreased. The total cholesterol (TC) and triacylglycerol (TG) levels increased significantly (P < 0.05, P < 0.01). The pathological examination of the kidneys showed some abnormalities. In contrast, these parameters were improved significantly in the free mycophenolate mofetil (MMF)-treated and liposome-contained mycophenolate mofetil (MMF)-treated groups. Conclusion The CellCept nanoliposomes have a good therapeutic effect on Adriamycin-induced nephrotic syndrome in rats.
authors.affiliation: a Department of Nephrology, Yantaishan Hospital , Yantai City, Shandong , China.
authors.forename: Jian
authors.initials: J
authors.lastname: Teng
authors.affiliation: b Department of Internal Medicine, Yantai Yuhuangding Hospital Laishan Branch , Yantai City, Shandong , China.
authors.forename: Lili
authors.initials: L
authors.lastname: Zang
authors.affiliation: a Department of Nephrology, Yantaishan Hospital , Yantai City, Shandong , China.
authors.forename: Lanzhi
authors.initials: L
authors.lastname: Li
authors.affiliation: a Department of Nephrology, Yantaishan Hospital , Yantai City, Shandong , China.
authors.forename: Xiaojun
authors.initials: X
authors.lastname: Qiu
authors.affiliation: a Department of Nephrology, Yantaishan Hospital , Yantai City, Shandong , China.
authors.forename: Yongmei
authors.initials: Y
authors.lastname: Liu
authors.affiliation: a Department of Nephrology, Yantaishan Hospital , Yantai City, Shandong , China.
authors.forename: Fang
authors.initials: F
authors.lastname: Sun
mesh_terms: D000818:Animals; D004195:Disease Models, Animal; D004317:Doxorubicin / Q000009:adverse effects / Q000494:pharmacology; D008081:Liposomes; D009173:Mycophenolic Acid / Q000737:chemistry / Q000494:pharmacology; D053758:Nanoparticles / Q000737:chemistry*; D009404:Nephrotic Syndrome / Q000188:drug therapy* / Q000378:metabolism / Q000473:pathology; D051381:Rats
chemical_list: D008081:Liposomes; D004317:Doxorubicin; D009173:Mycophenolic Acid
keywords: CellCept nanoliposome; nephrotic syndrome; rats